Excluding data gathering and analysis, average time from manuscript submission to publication into a highly-respected, peer-reviewed, top-tier scientific journal is just over a year.
Based upon ACT's timeline of first injections in July 2011 and PRELIMINARY data in October 2011, at the earliest, print publication will not occur until the fourth quarter of 2012, with online publication possibly a few weeks before.
Also, statistical significance cannot be established with just two patients. There has to be a major, unprecedented breakthrough to supplant that shortcoming.
The review process cannot/must not be rushed or expedited.
Any mistake or oversight resulting in a rejection or retraction would be devastating.
Although more risky, the mass media would be a more direct and expedient channel. But only a dramatic, unequivocal visual rescue or improvement would be enough to galvanize public interest and rally the financial/investment industry to ACT's cause.
Anything less would fall short.